Table 3.
Univariate and multivariate analysis of OS.
| Variable | Parameter | Median OS | 95% CI | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | ||||
| Age | <54 | 26.4 | 27.1–35.0 | 1.000 | 0.259 | — | — |
| ≥54 | 25.5 | 23.8–29.8 | 1.394 (0.783–2.484) | — | |||
| Gender | Male | 28.2 | 25.9–32.4 | 1.000 | 0.663 | — | — |
| Female | 25.5 | 24.8–33.7 | 1.137 (0.639–2.021) | — | |||
| ECOG performance status | 0 | 29.4 | 28.5–35.5 | 1.000 | <0.001 | 1.000 | 0.018 |
| 1–2 | 22.3 | 21.7–29.0 | 3.907 (2.177–7.012) | 2.237 (1.146–4.367) | |||
| Tumor location | Left colon | 26.8 | 25.7–35.6 | 1.000 | 0.657 | — | — |
| Right colon | 23.7 | 23.0–31.5 | 0.733 (0.376–1.429) | — | |||
| Rectum | 26.2 | 25.1–34.4 | 0.847 (0.429–1.617) | — | |||
| Clinical T stage | T2 | 30.1 | 22.5–35.8 | 1.000 | 0.551 | — | — |
| T3 | 23.2 | 23.3–30.8 | 0.940 (0.314–2.813) | — | |||
| T4 | 26.3 | 25.4–36.6 | 1.392 (0.726–2.670) | — | |||
| Lymph node metastasis | No | 30.1 | 24.2–38.0 | 1.000 | 0.644 | — | — |
| Yes | 24.9 | 25.1–32.1 | 1.191 (0.568–2.495) | — | |||
| Distant metastasis | No | 30.5 | 29.3–36.3 | 1.000 | <0.001 | 1.000 | 0.020 |
| Yes | 22.2 | 20.7–27.2 | 0.464 (0.340–0.635) | 2.757 (1.171–6.492) | |||
| Neoadjuvant chemotherapy regimen | FOLFOX | 33.0 | 29.6–39.8 | 1.000 | 0.575 | — | — |
| XELOX | 24.5 | 23.6–29.0 | 1.041 (0.432–2.510) | — | |||
| FOLFIRI | 22.6 | 19.9–35.1 | 1.402 (0.583–3.370) | — | |||
| Pathological differentiation | Low grade | 25.6 | 20.1–39.2 | 1.000 | 0.985 | — | — |
| Intermediate grade | 26.4 | 26.6–35.9 | 1.099 (0.274–4.413) | — | |||
| High grade | 22.3 | 15.3–33.8 | 1.017 (0.303–3.408) | — | |||
| NLR | <2.22 | 30.1 | 29.2–36.8 | 1.000 | <0.001 | 1.000 | 0.017 |
| ≥2.22 | 22.9 | 22.2–28.6 | 4.204 (2.260–7.820) | 2.336 (1.165–4.687) | |||
| PLR | <114.15 | 26.6 | 27.3–34.6 | 1.000 | 0.023 | 1.000 | 0.954 |
| ≥114.15 | 23.6 | 23.8–31.1 | 1.934 (1.093–3.419) | 0.978 (0.466–2.054) | |||
| LMR | <4.27 | 22.1 | 22.1–28.2 | 1.000 | <0.001 | 1.000 | 0.125 |
| ≥4.27 | 30.9 | 29.3–37.2 | 0.315 (0.175–0.567) | 0.446 (0.159–1.252) | |||
| SII | <437.72 | 26.6 | 27.3–34.8 | 1.000 | 0.013 | 1.000 | 0.266 |
| ≥437.72 | 23.6 | 23.8–31.0 | 2.059 (1.161–3.650) | 0.572 (0.213–1.531) | |||
| LDH | <220 | 26.0 | 26.9–32.2 | 1.000 | 0.668 | — | — |
| ≥220 | 19.5 | 12.1–33.7 | 1.366 (0.328–5.684) | — | |||
| CA19-9 | <22 | 25.5 | 26.1–33.3 | 1.000 | 0.333 | — | — |
| ≥22 | 26.4 | 25.0–33.7 | 1.344 (0.739–2.445) | — | |||
NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, LMR lymphocyte-to-monocyte ratio, SII systemic immune-inflammation index, LDH lactic dehydrogenase, CA 19-9 carbohydrate antigen 19-9.